Changjiang Pharmaceutical Group Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Ming Luo

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	2.4yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	2.4yrs

Recente managementupdates

Recent updates

Revenues Not Telling The Story For Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) After Shares Rise 45%

Sep 30

Investors Don't See Light At End Of Changjiang Pharmaceutical Group Co., Ltd.'s (SZSE:300391) Tunnel And Push Stock Down 31%

Aug 11

Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough

Jun 17

Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Looks Inexpensive After Falling 38% But Perhaps Not Attractive Enough

Apr 17

Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Not Doing Enough For Some Investors As Its Shares Slump 25%

Feb 27

CEO

Ming Luo (47 yo)

2.4yrs

Tenure

CN¥732,000

Compensatie

Mr. Ming Luo is Non-Independent Director of Changjiang Pharmaceutical Group Co., Ltd. (formerly known as Kangyue Technology Co., Ltd.) from June 22, 2022. Mr. Luo is the General Manager of Changjiang Pharm...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ming Luo	GM & Director	2.4yrs	CN¥732.00k	geen gegevens
Luhong Ning	Director	2.4yrs	CN¥350.00k	geen gegevens
Xuan Li	Non-Independent Director	4.7yrs	CN¥53.30k	geen gegevens
Qingkai Han	Non-Independent Director	2.4yrs	CN¥53.30k	geen gegevens
Yuanjun Deng	Independent Director	2.4yrs	CN¥53.30k	geen gegevens
Kangbing Wu	Independent Director	2.4yrs	CN¥53.30k	geen gegevens
Xia Lan	Independent Director	2.4yrs	CN¥53.30k	geen gegevens
Xian Li	Chairman of the Supervisory Board	2.4yrs	geen gegevens	geen gegevens
Shoujun Zhao	Non-Independent Director	less than a year	geen gegevens	geen gegevens
Yinghui Gao	Non-Independent Director	less than a year	geen gegevens	geen gegevens
Hao Weng	Non-Independent Director	less than a year	geen gegevens	geen gegevens
Bo Wang	Non-Independent Director	less than a year	geen gegevens	geen gegevens

2.4yrs

Gemiddelde duur

47yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 300391 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.4 jaar), wat duidt op een nieuw bestuur.

Changjiang Pharmaceutical Group Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Changjiang Pharmaceutical Group Co., Ltd. Approves Election of Board of Directors

Changjiang Pharmaceutical Group Co., Ltd. Approves Board Changes

Changjiang Pharmaceutical Group Co., Ltd., Annual General Meeting, May 21, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

Kangyue Technology Co., Ltd. Announces Board Appointments

Recent updates

Third quarter 2024 earnings released: CN¥0.081 loss per share (vs CN¥0.26 loss in 3Q 2023)

Changjiang Pharmaceutical Group Co., Ltd. Approves Election of Board of Directors

Revenues Not Telling The Story For Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) After Shares Rise 45%

Changjiang Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Investors Don't See Light At End Of Changjiang Pharmaceutical Group Co., Ltd.'s (SZSE:300391) Tunnel And Push Stock Down 31%

Changjiang Pharmaceutical Group Co., Ltd. Approves Board Changes

Changjiang Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough

New major risk - Financial position

Changjiang Pharmaceutical Group Co., Ltd., Annual General Meeting, May 21, 2024

Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Looks Inexpensive After Falling 38% But Perhaps Not Attractive Enough

Changjiang Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Not Doing Enough For Some Investors As Its Shares Slump 25%

New minor risk - Share price stability

Changjiang Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: CN¥0.26 loss per share (vs CN¥0.19 profit in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.004 loss per share (vs CN¥0.16 loss in 2Q 2022)

Changjiang Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 23, 2023

Full year 2022 earnings released: CN¥0.066 loss per share (vs CN¥0.14 profit in FY 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.036 in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.16 loss per share (vs CN¥0.07 profit in 2Q 2021)

High number of new and inexperienced directors

Kangyue Technology Co., Ltd. Announces Board Appointments

First quarter 2022 earnings: EPS misses analyst expectations

High number of new directors

Now 21% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.036 (vs CN¥0.024 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.07 (vs CN¥0.007 loss in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.014 loss in 1Q 2020)

Kangyue Technology Co., Ltd. announced that it expects to receive CNY 140 million in funding

New 90-day low: CN¥9.48

New 90-day low: CN¥15.66

Third quarter earnings released

New 90-day high: CN¥20.01

New 90-day high: CN¥19.56

Kangyue Technology Co., Ltd. (SZSE:300391) intends to acquire 52.8% stake in Hubei Changjiangxing Pharmaceutical Co.,Ltd from Hubei Changjiang Pharmacy Chain Co., Ltd., Shenzhen Shengshi Fenghua Enterprise Management Co., Ltd. and Wang Dongxiang for approximately CNY 1.4 billion.

First half earnings released

New 90-day high - CN¥18.60

Kangyue Technology Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - CN¥15.14

Liu Lili completed the acquisition of a 5% stake in Kangyue Technology Co., Ltd. (SZSE:300391) from Beijing Wenming Investment Fund Management Co., Ltd.

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd